| 
							
								 
										시장보고서
									 
									
											
												상품코드
											
										 
										
											1440015
										 
									세계의 중합효소 연쇄 반응(PCR) 시장 : 인사이트, 경쟁 구도 및 시장 예측(2030년)Polymerase Chain Reaction - Market Insights, Competitive Landscape, and Market Forecast - 2030 | 
						||||||
세계의 중합효소 연쇄 반응(PCR) 시장 규모는 2023년 49억 달러로 평가되었고, 2030년까지 80억 4,000만 달러에 이를 전망이며, 2024년부터 2030년까지 예측기간에 CAGR 8.66%의 성장이 전망됩니다. 시장은 병원체에 의해 유발되는 질환의 유병률의 상승, 임상 진단 분야에서의 이용 증가, 더욱 그 정밀도를 높이기 위한 신기술의 진보 등의 요인에 의해 수익이 증가할 전망이며, 예측 기간(2024-2030년)에 시장의 대폭적인 수익 성장이 초래될 것으로 예측됩니다.
중합효소 연쇄 반응(PCR) 시장 역학
중합효소 연쇄 반응(PCR) 시장의 주목할 만한 촉진요인 중 하나는 임상 진단 분야에서 PCR 기술의 사용 증가입니다. COVID-19 팬데믹에서 SARS-CoV의 존재를 검출하는 방법으로서 실시간 RT-PCR 기술의 사용은 의료 산업에 유익한 것으로 입증되었습니다. 세계보건기구(2019)에 따르면 RT-PCR법은 SARSCOVID-19의 검출을 위한 골든스탠다드입니다. 예를 들어, 세계보건기구(2023)의 보고서에 따르면 세계 5억 4,092만 3,532명의 COVID-19가 확인되었으며, 모든 사례는 RT-PCR 검사를 사용하여 검출되었습니다. RT-PCR 방법의 사용과 관련된 주된 이유는 높은 감도 및 특이성입니다. RT-PCR법은 COVID-19의 검출에만 적용할 수 있을 뿐만 아니라, 암세포의 검출을 위한 종양학에서도 사용되고 있습니다. 예를 들어 Annals of Surgery(2019)에 따르면 RT-PCR은 대장암의 사례에서 순환암세포의 관찰에 가장 효과적인 방법이었습니다.
중합효소 연쇄 반응(PCR) 시장의 성장을 초래하는 또 다른 주요 요인 중 하나는 유전성 질환의 진단에 대한 사용 증가입니다. 예를 들어, Swedish Agency for Health Technology Assessment and Assessment of Social Services(2019)에 따르면 유전성 질환이 의심되는 사례의 80%에서 RT-PCR 방법이 전통적인 진단 방법의 대부분을 대체합니다. 중합효소 연쇄 반응(PCR) 시장의 성장을 초래하는 또 다른 주요 요인은 제품의 효능을 향상시키기 위해 PCR 기술에서 수행되는 지속적인 기술의 발전입니다. 예를 들어 2020년 12월 Stilla Technologies는 Crystal Digital PCR(nacia multiplex PCR Mix, nacia PCR Mix)에서 최적의 성능을 발휘하는 Polymerase Chain Reaction Mix 시약 라인을 출시했습니다. 이들은 디지털 PCR 용도에서 탁월한 결과와 견고성을 제공하도록 최적화되었습니다.
비슷한 발전으로 DNA/RNA 분석 전문가인 PCR Biosystems는 2022년 3월 신속하고 견고한 DNA 및 RNA 증폭을 위한 IsoFast Bst Polymerase 시약 세트를 출시했습니다. 그러나 대체 요법의 가용성과 중합효소 연쇄 반응(PCR) 장비 및 시약의 높은 비용이 중합효소 연쇄 반응(PCR) 시장의 성장 억제요인으로 작용할 수 있습니다.
중합효소 연쇄 반응(PCR) 시장은 COVID-19 팬데믹에 의해 시장이 급성장한 시기가 있었습니다. COVID-19 팬데믹은 의료 서비스의 대규모 재편성과 의료 처치의 실시를 가져왔으며, 세계 보건기구(2019)에 따르면 RT-PCR 검사 보고가 감염 검출의 기준이 되고 있었습니다. 중합효소 연쇄 반응(PCR) 시장에 참여하는 모든 주요 시장 기업은 COVID-19 단계 동안 수익의 강력한 성장을 경험했습니다. 예를 들어 Thermo Fisher Scientific Corporation의 연례 보고서(2023)에 따르면 회사의 수익 점유율은 2018년에 비해 26% 증가한 322억 2,000만 달러로 GAAP 희박화 후 EPS는 74% 증가했습니다. 또 다른 예에서 Qiagen Annual Report(2023)에 따르면 Qiagen은 2018년에 비해 수익 점유율이 22.53% 급증했습니다. 세계 COVID-19 환자는 감소하고 있지만, 여전히 중합효소 연쇄 반응(PCR)에 기초한 검사는 임상진단 및 연구에서 일정한 용도로 증가하는 경향이 있으며, 2024년부터 2030년까지 예측기간에 중합효소 연쇄 반응(PCR) 시장 성장을 가속하고 있습니다.
이 보고서는 세계의 중합효소 연쇄 반응(PCR) 시장에 대한 조사 분석을 통해 시장 규모 및 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.
Polymerase Chain Reaction Market By Type (Conventional PCR, Real-Time RT-PCR, Digital PCR, Others) By Application (Infectious Diseases, Cancer, Hereditary Disorders, And Others), By End-User (Hospitals & Clinics, Academic & Research Labs, Others) and by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to rise in the prevalence of infectious diseases, increased applications in clinical diagnostics, and constant advancements in pcr technology for efficient use in biomedical sciences.
The Global Polymerase Chain Reaction market was valued at USD 4.90 billion in 2023, growing at a CAGR of 8.66% during the forecast period from 2024 to 2030 to reach USD 8.04 billion by 2030. The Polymerase Chain Reaction market is slated to witness increasing revenue owing to factors such as a rise in the prevalence of diseases caused by pathogens, increasing applications in the field of clinical diagnostics, along with latest technological advancements to further enhance its accuracy is expected to result in appreciable revenue growth in the Polymerase Chain Reaction market during the forecast period (2024-2030).
Polymerase Chain Reaction Market Dynamics:
One of the noteworthy drivers of the Polymerase Chain Reaction market is the increasing use of PCR techniques in the clinical diagnostics sector. The use of the real-time RT-PCR technique as a way to detect the presence of SARS-CoV during the COVID-19 pandemic has proved to be a boon for the healthcare industry. According to the World Health Organization (2019), the RT-PCR technique is the golden standard for the detection of SARS coronavirus. For instance, as per reports from World Health Organization (2023), there have been 540,923,532 confirmed cases of Covid-19 worldwide, and every case was detected through the use of an RT-PCR test. The main reasons associated with the use of the RT-PCR technique are its high sensitivity and specificity. Not only is the RT-PCR solely applicable for the detection of COVID-19, but it is also used in oncology for the detection of cancer cells. For example, according to the Annals of Surgery (2019), RT-PCR was the most effective technique for the observation of circulating cancer cells in cases of colorectal cancer.
One of the other prominent factors responsible for the growth of the Polymerase Chain Reaction Market is its increasing use in the diagnosis of genetic disorders. For example, according to the Swedish Agency for Health Technology Assessment and Assessment of Social Services (2019), the RT-PCR technique has replaced most of the conventional diagnostic methods in 80% of suspected cases of genetic disorders. Another key factor responsible for the growth of the Polymerase Chain Reaction market is the continuous technological advancements taking place in PCR technology to improve product efficacy. For instance, in December 2020, Stilla Technologies launched a Polymerase Chain Reaction Mix reagent line for optimal performance with Crystal Digital PCR (nacia multiplex PCR Mix and nacia PCR Mix), which are optimized for better results and robustness for digital PCR applications.
In a similar development, in March 2022, PCR Biosystems, specialists in DNA and RNA analysis launched a set of IsoFast Bst Polymerase reagents for rapid, robust DNA & RNA amplification. However, the availability of alternative therapies and the high cost of the Polymerase Chain Reaction machine and reagents may act as restraining factors to the Polymerase Chain Reaction market growth.
The Polymerase Chain Reaction market reported a period of rapid market growth due to the COVID-19 pandemic. The COVID-19 pandemic resulted in the massive reorganization of the healthcare services and carrying out of medical procedures, where the RT-PCR test reports were the measure for the detection of infection, as per the World Health Organization (2019). All the key market players involved in the Polymerase Chain Reaction Market experienced robust growth in their revenue during the phases of COVID-19. For example, according to the annual report of Thermo Fisher Scientific Corporation (2023), the revenue share of the company increased by 26% to 32.22 billion USD, and the GAAP diluted EPS increased by 74%, as compared to 2018. In another instance, according to the Qiagen Annual Report (2023), Qiagen saw a jump in its revenue share by 22.53% as compared to 2018. Although the global COVID-19 cases reducing, still Polymerase Chain Reaction based test is on the rise because of their constant applications in clinical diagnostics and research, which is uplifting the Polymerase Chain Reaction market growth during the forecast period from 2024-2030.
Polymerase Chain Reaction Market Segment Analysis:
Polymerase Chain Reaction Market by Type (Conventional PCR, Real-time RT-PCR, Digital PCR, and Others), Application (Infectious diseases, Cancer, Hereditary disorders, and Others), End-user (Hospitals & Clinics, Academic & Research Labs, Others), Geography (North-America, Europe, Asia-Pacific, Rest of the World)
Based on the Application segment of the Polymerase Chain Reaction Market, the infectious diseases category is projected to register significant growth in revenue in the Polymerase Chain Reaction market during the forecast period (2024-2030). This can be ascribed to the increasing prevalence of infectious diseases caused by viruses, bacteria, fungi, and other pathogens. With one of the most infectious and recent examples of infectious disease being COVID-19, other hazardous diseases caused by pathogens are HIV AIDS, and Tuberculosis, caused by viruses and bacteria respectively. As per reports from World Health Organization (2023), there were 37.7 billion cases of HIV-AIDS globally, by the end of 2020.
The RT-PCR technique is regarded as the alternative gold standard for the detection of HIV AIDS. In cases of bacterial infection diseases like Tuberculosis, the RT-PCR technique shows high sensitivity and specificity during diagnosis. The RT-PCR technique also has its advantages in oncological studies. As per reports from World Health Organization (2023) cancer accounted for approximately 10 million deaths, in the year 2020. According to the same source, one of the primary reasons for cancer deaths was the late diagnosis of the disease, to which the Polymerase Chain Reaction appears to be the fastest and most sensitive test for the detection of tumors.
Therefore, considering the growing demand for this product type, numerous new products are being launched in the market with technological advancements. For example, in March 2022, MatMa Corporation launched MYRTA, a new hand-held Real-Time RT-PCR device for Point-of-Care (POC) and Over-the-Counter (OTC) molecular diagnostics.
Thus, considering the rising prevalence of various infectious diseases and their growing popularity among end users, the application segment is expected to generate considerable revenue thereby pushing the overall growth of the global Polymerase Chain Reaction market during the forecast period.
North America is expected to dominate the overall Polymerase Chain Reaction Market:
Among all the regions, North America is expected to lead in revenue generation in the global Polymerase Chain Reaction market. This can be ascribed to the growing prevalence of infectious diseases and the increasing number of clinical research studies in the North American region. According to the Centre for Disease Prevention and Control (2023), 6 in 10 people in the United States were burdened with a chronic disease, and 4 in 10 people had two or more diseases in the year 2023. The World Health Organization (2023) statistics show that the COVID-19 pandemic has severly impacted the U.S., with 88,932,987 cases and 1,018,035 deaths, by July 14, 2022. Due to such a high prevalence of infectious diseases in the United States, it expands the way for more amount of clinical studies and the latest diagnostic technological developments.
One of the other prominent factors supporting the growth of the North America Polymerase Chain Reaction market is the rising case of genetic disorders in the North American region. As per reports from the Centre for Disease Control and Prevention (2023), millions of people are affected by inherited genetic disorders such as cystic fibrosis, sickle-cell anemia, Lynch syndrome, etc. every year. Some genetic disorders are not diagnosed at birth but lead to severe consequences at a later stage due to late detection of the syndrome. For example, the report from the World Health Organization, Regional Office for the Eastern Mediterranean (2023), shows that cases with genetic disorders account for 2%-5% of all live births, 30% of the affected account for hospital admissions at a later stage, and 50% account for deaths during childhood in the year 2020, in industrialized countries.
The presence of a large patient population base in the North American region, also opens up the way for new technologies and collaborations to take place in clinical diagnostics areas. For example, in June 2022, Bio-Rad collaborated with Seegene Inc. for the production of molecular diagnostic products related to infectious diseases. Through this collaboration, Seegene started to provide diagnostic tests for use on Bio-Rad's LFX960x Real-Time PCR System for commercial use in the U.S. market. In another instance, according to the American Chemical Society (2023), researchers devised a postage stamp-sized polydimethylsiloxane chip with microchambers arrays in the PCR. Although the amplification efficiency of the chip-encoded PCR was 91% as compared to 98% in standard PCR, the chip-encoded PCR takes approximately 5 minutes for detection as compared to an hour in conventional PCRs. The source further stated that the technique will get commercialized in the future and could be used for rapid detection diagnosis during severe cases of pandemics.
Therefore, the presence of a large patient population base with infectious diseases and genetic disorders, coupled with a rise in technological advancements and clinical research studies is expected to bolster the growth of the Polymerase Chain Reaction market in the North American region during the forecast period.
Polymerase Chain Reaction Market Key Players:
Some of the key market players operating in the Polymerase Chain Reaction market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Qiagen, Agilent Technologies Inc., Standard Biotools, F. Hoffmann-La Roche Ltd., Eppendorf, Avance Biosciences Inc., Merck & Co. Inc., Abbott, Promega Corporation, Takara Bio Inc., Endress+Hauser Group Services AG, BioMerieux, GenMark Diagnostics Inc., Grifols SA, Hologic Inc., BD, Sysmex Corporation, Stilla, and others.
Recent Developmental Activities in the Polymerase Chain Reaction Market:
In January 2022, Qiagen collaborated with Atila Biosystems and Actome GmbH for the use of QIAcuity digital PCR instruments. Atila Biosystems will provide non-invasive prenatal testing and Actome extends QIAcuity reach from genomics to proteomics.
In June 2022, Bio-Rad collaborated with Seegene Inc., for the production of molecular diagnostic products related to infectious diseases. Through this, Seegene shall provide diagnostic tests in U.S markets for use on Bio-Rad's LFX960x real-time PCR system.
In March 2022, MatMa Corporation launched MYRTA, a new hand-held PCR device for POC & OTC Molecular Diagnostics.
Key Takeaways from the Polymerase Chain Reaction Market Report Study
Target Audience who can be benefited from this Polymerase Chain Reaction Market Report Study
Frequently Asked Questions for Polymerase Chain Reaction Market:
Polymerase Chain Reaction is a laboratory technique based on the enzymatic replication of DNA. Short strands of DNA are amplified using enzymes that are primer-mediated. Through this, million to billion copies of DNA can be produced, leading to better observation and conduct of research studies.
The Global Polymerase Chain Reaction market was valued at USD 4.90 billion in 2023, growing at a CAGR of 8.66% during the forecast period from 2024 to 2030 to reach USD 8.04 billion by 2030.
The Polymerase Chain Reaction Market is expected to grow significantly owing to factors such as a rise in the prevalence of diseases caused by pathogens and increasing applications in the field of clinical diagnostics. The rapidly growing technological advancements taking place in the Polymerase Chain Reaction market with better technologies for delivering precise results in a quick time are further expected to result in appreciable revenue growth in the Polymerase Chain Reaction market during the given forecast period (2024-2030).
Some of the key market players operating in the Polymerase Chain Reaction market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Qiagen, Agilent Technologies Inc., Standard Biotools, F. Hoffmann-La Roche Ltd., Eppendorf, Avance Biosciences Inc., Merck & Co. Inc., Abbott, Promega Corporation, Takara Bio Inc., Endress+Hauser Group Services AG, BioMerieux, GenMark Diagnostics Inc., Grifols SA, Hologic Inc., BD, Sysmex Corporation, Stilla, and others.
North America is expected to dominate the overall Polymerase Chain Reaction market during the forecast period, 2024 to 2030. This can be ascribed to the presence of a huge number of cases of infectious diseases and genetic disorders in the North American region, leading to more diagnostic procedures. In addition, it is a highly potent market in terms of technological developments and new product launches along with the presence of key market players among other factors in the region.